Auxogyn Raises $18 Million in Series B Financing

On June 5, 2012, privately held reproductive health company Auxogyn announced that it has raised $18 million through a Series B financing. The financing was led by new investor SR One and included participation from Series A investors Kleiner Perkins Caufield and Byers, TPG Biotech, and Merck Serono Ventures. Wilson Sonsini Goodrich & Rosati's Marty Waters and Dan Koeppen represented SR One, the independent corporate venture capital arm of GlaxoSmithKline, in connection with this matter.

The proceeds from the financing will be used to support regulatory clearance and the commercial launch of Auxogyn's non-invasive test designed to provide objective information regarding the viability of embryos during in vitro fertilization procedures.

For more information, please see Auxogyn's press release.